Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ehime Macular Edema Study: Tofogliflozin for Diabetic Macular Edema
jRCTs061180065Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tofogliflozin in type 2 diabetes mellitus (T2DM), diabetic macular edema (DME) and diabetic retinopathy (DR), sponsored by Kowa Company, Ltd. Primary endpoint: Change in central retinal thickness at 52 weeks. Started May 2019; status: recruiting.
02
Drugs
tofogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic macular edema (DME)diabetic retinopathy (DR)
Beyond the preview
Go deeper on jRCTs061180065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180065.